Acute hepatic porphyria and cancer risk: a nationwide cohort study

• Autores: C.M. Baravelli, A.K. Aarsand, S. Sandberg
• Localización: Journal of Internal Medicine, ISSN-e 1365-2796, Vol. 282, Nº. 3, 2017, págs. 229-240
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Acute hepatic porphyria (AHP) is considered to be a risk factor for primary liver cancer (PLC), but varying risk estimates have been published.

    Objectives Our aim was to investigate the risk of PLC and other cancers in persons with AHP using a nationwide cohort design. Given that greater numbers of women than men tend to have manifest and more severe AHP, a further aim was to investigate sex differences in this risk.

    Methods The study sample consisted of all Norwegian residents aged 18 years or older during the period 2000–2011. Persons with AHP (n = 251) were identified through the Norwegian Porphyria Centre, and patients with a cancer diagnosis were identified by linkage to the Cancer Registry of Norway.

    Results For persons with AHP, the annual incidence rate of PLC was 0.35%. PLC risk was substantially higher for individuals with an AHP diagnosis compared to the reference population [adjusted hazard ratio (aHR) 108, 95% confidence interval (CI) 56–207]. In a meta-analysis of published studies on PLC and AHP, including ours, women had a higher risk than men. In addition, our results suggested that persons with AHP may have increased risks of kidney (aHR 7.4, 95% CI 2.4–23.1) and endometrial cancers (aHR 6.2, 95% CI 2.0–19.3).

    Conclusions Our findings confirmed a substantially higher risk of PLC associated with AHP compared to the general population. In a meta-analysis, the risk was shown to be greater for women than men. The novel findings of a moderate to substantial association between AHP and kidney and endometrial cancers should be investigated further.